Abstract:Background YTH domain family (YTHDF) 2 acts as a “reader” protein for RNA methylation, which is important in tumor regulation. However, the effect of YTHDF2 in liver hepatocellular carcinoma (LIHC) has yet to be elucidated. Methods We explored the role of YTHDF2 in LIHC based on publicly available datasets [The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO)]. A bioinformatics approach was employed to analyze YTHDF2 . Logistic regression analyses were applied to analyze the correlation between YTHDF2 expression and clinical characteristics. To evaluate the effect of YTHDF2 on the prognosis of LIHC patients, we used Kaplan–Meier (K–M) curves. Gene set enrichment analysis (GSEA) was undertaken using TCGA dataset. Univariate and multivariate Cox analyses were used to ascertain the correlations between YTHDF2 expression and clinicopathologic characteristics with survival. Genes co-expressed with YTHDF2 were identified and detected using publicly available datasets [LinkedOmics, University of California, Santa Cruz (UCSC), Gene Expression Profiling Interactive Analysis (GEPIA), and GEO]. Correlations between YTHDF2 and infiltration of immune cells were investigated by Tumor Immune Estimation Resource (TIMER) and GEPIA. Results mRNA and protein expression of YTHDF2 was significantly higher in LIHC tissues than in non-cancerous tissues. High YTHDF2 expression in LIHC was associated with poor prognostic clinical factors (high stage, grade, and T classification). K–M analyses indicated that high YTHDF2 expression was correlated with an unfavorable prognosis. Univariate and multivariate Cox analyses revealed that YTHDF2 was an independent factor for a poor prognosis in LIHC patients. GSEA revealed that the high-expression phenotype of YTHDF2 was consistent with the molecular pathways implicated in LIHC carcinogenesis. Analyses of receiver operating characteristic curves showed that YTHDF2 might have a diagnostic value in LIHC patients. YTHDF2 expression was associated positively with SF3A3 expression, which implied that they may cooperate in LIHC progression. YTHDF2 expression was associated with infiltration of immune cells and their marker genes. YTHDF2 had the potential to regulate polarization of tumor-associated macrophages, induce T-cell exhaustion, and activate T-regulatory cells. Conclusion YTHDF2 may be a promising biomarker for the diagnosis and prognosis of LIHC and may provide new directions and strategies for LIHC treatment.

Overexpression of YTHDC2 Contributes to the Progression of Prostate Cancer and Predicts Poor Outcomes in Patients with Prostate Cancer.

Eukaryotic Translation Initiation Factor 5A2 is Highly Expressed in Prostate Cancer and Predicts Poor Prognosis.

The Roles and Mechanisms of YTH Domain-Containing Proteins in Cancer Development and Progression.

Elevated CISD2 Expression Predicts Poor Diagnosis and Promotes Invasion and Migration of Prostate Cancer Cells.

Downregulation of N-6-methyladenosine Binding YTHDF2 Protein Mediated by Mir-493-3p Suppresses Prostate Cancer by Elevating N-6-methyladenosine Levels

The Role of YTH Domain Containing 2 in Epigenetic Modification and Immune Infiltration of Pan-Cancer

Expression Andclinical Significance of YTH Domain Containing Family 2 in Hepatocellular Carcinoma

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy

Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma

Overexpression of WDFY2 Inhibits Prostate Cancer Cell Growth and Migration Via Inactivation of Akt Pathway.

YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m 6 A modification

Expression of YT Domain Family Protein in Oral Squamous Cell Carcinoma and Its Correlation with the Prognosis.

YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer

Systematic Analyses of the Role of the Reader Protein of N6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma

ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner

Downregulation of M6a Reader YTHDC2 Promotes Tumor Progression and Predicts Poor Prognosis in Non‐small Cell Lung Cancer

The N6-methyladenosine Reader Protein YTHDC2 Promotes Gastric Cancer Progression Via Enhancing YAP Mrna Translation

YTHDF2 promotes gastric cancer progression and enhances chemoradiotherapy resistance

YTHDC2 Retards Cell Proliferation and Triggers Apoptosis in Papillary Thyroid Cancer by Regulating CYLD-Mediated Inactivation of Akt Signaling

Downregulation of <scp> m <sup>6</sup> A </scp> reader <scp>YTHDC2</scp> promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

The m6A reader protein YTHDC2 is a potential biomarker and associated with immune infiltration in head and neck squamous cell carcinoma